These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31980251)

  • 21. Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease.
    Yueh MF; He F; Chen C; Vu C; Tripathi A; Knight R; Karin M; Chen S; Tukey RH
    Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31259-31266. PubMed ID: 33229553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.
    Tanaka N; Takahashi S; Zhang Y; Krausz KW; Smith PB; Patterson AD; Gonzalez FJ
    Biochim Biophys Acta; 2015 Jul; 1852(7):1242-52. PubMed ID: 25736301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis.
    Zhu Y; Tan JK; Wong SK; Goon JA
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
    Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients.
    Franck M; John K; Al Aoua S; Rau M; Geier A; Schattenberg JM; Wedemeyer H; Schulze-Osthoff K; Bantel H
    Liver Int; 2023 Dec; 43(12):2668-2679. PubMed ID: 37534777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake.
    Sarkar S; Chen S; Spencer B; Situ X; Afkarian M; Matsukuma K; Corwin MT; Wang G
    Metab Syndr Relat Disord; 2021 Nov; 19(9):491-497. PubMed ID: 34448598
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
    Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
    FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
    Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
    Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 36. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice.
    Majeed M; Majeed S; Nagabhushanam K; Lawrence L; Mundkur L
    Sci Rep; 2020 May; 10(1):7440. PubMed ID: 32366854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.
    Henriksson E; Andersen B
    Front Endocrinol (Lausanne); 2020; 11():601349. PubMed ID: 33414764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced Oxidative Stress and Enhanced FGF21 Formation in Livers of Endurance-Exercised Rats with Diet-Induced NASH.
    Henkel J; Buchheim-Dieckow K; Castro JP; Laeger T; Wardelmann K; Kleinridders A; Jöhrens K; Püschel GP
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31717358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.